Extracellular Domain Protein (ECD)

DIMA Biotechnology offers over 800 ECD proteins covering more than 600 single pass membrane protein targets. All the proteins were made using HEK293 mammalian cell secretion expression system to ensure the close-to-native structures and post-translational modifications of the target proteins. We also implemented a strict quality control process, including purity testing, antibody-drug interaction verification, freezing and thawing tests, thermal stability tests, etc. 

Applications:

  • Immunogens for antibody drug development
  • Reagents used for CAR-T positive cell monitoring
  • Reagents for antibody screening and functional testing
  • Reagents for antibody affinity measurement
View All ECD Proteins
protein

Immune checkpoints are a class of proteins that regulate tumor immune microenvironment.

They can be classified into two categories, costimulatory immune checkpoints, such as OX40, GITR, ICOS, etc.; and co-suppressive immune checkpoints, such as PD1, CTLA-4, etc.

Right now there are a number of FDA approved drugs on co-suppressive targets, such as Yervoy, anti-CTLA-4 monoclonal antibody, Keytruda, anti-PD-1 monoclonal antibody and Tecentriq, anti-PD-L1 monoclonal antibody.

pages-416107bc534d939 1

DIMA Biotechnology LTD provide a full spectrum of functional proteins of new CAR T-cell targets.

All the proteins were made by using HEK293 mammalian cell secretion expression system and we implemented a strict quality control process, including purity testing, antibody-drug interaction verification, freezing and thawing Tests, thermal stability tests, etc.

pages-cvsdvdfffffb 1

In recent years, the biopharmaceutical market is growing rapidly.

Compared with small molecule drugs, antibody drugs exhibit higher specificity and selectivity.

Therefore, it showed tremendous progresses in the treatment of hematological cancers and autoimmune diseases.

Due to complex tumor immune microenvironment, the development of therapeutic antibody drugs for solid tumor is more challenging.

Latest News

 

ADC赛道新爆点-双载荷ADC

对于传统ADC药物的迭代优化主 [...]

NPY受体家族:疾病治疗的“新靶点”与“老难题”

在神经精神疾病、代谢紊乱、癌症 [...]

盘点|双抗ADC新赛道上的靶点

2025 AACR年会上,中国 [...]

邀请函|缔码生物与您相约2025 CAS年会与2025 PEGS峰会

缔码生物将携5000+现货先导 [...]

新品发布I解锁Biotin/PE标记抗体

标记抗体及其应用 1.1 标记 [...]